Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin [Internet]. 2019;69:7–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30620402
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–691.
   PubMed Web of Science ®Google Scholar
• Al-Husseini MJ, Saad AM, Jazieh KA, et al. Outcome disparities in colorectal cancer: a SEER-based comparative analysis of racial subgroups. Int J Colorectal Dis. 2019;34:285–292.
   PubMed Web of Science ®Google Scholar
• Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer. 2018;18:1–11.
   PubMed Web of Science ®Google Scholar
• Fiorentini G, Sarti D, Aliberti C, et al. Multidisciplinary approach of colorectal cancer liver metastases. World J Clin Oncol. 2017;8:190.
   PubMed Web of Science ®Google Scholar
• Mattar RE, Al-Alem F, Simoneau E, et al. Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. World J Gastroenterol. 2016;22:567–581.
   PubMed Web of Science ®Google Scholar
• De Ridder JAM, Van Der Stok EP, Mekenkamp LJ, et al. Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection. Eur J Cancer [Internet]. 2016;59:13–21.
   PubMed Web of Science ®Google Scholar
• Lai H-W, Wei J-C-C, Hung H-C, et al. Impact of treatment modality on clinical outcome in metastatic colorectal cancer patients stratified by metastatic sites. Postgrad Med [Internet]. 2019;131:163–170.
   PubMed Web of Science ®Google Scholar
• Veereman G, Robays J, Verleye L, et al. Pooled analysis of the surgical treatment for colorectal cancer liver metastases. Crit Rev Oncol Hematol [Internet]. 2015;94:122–135.
   PubMed Web of Science ®Google Scholar
• Gill S, Liu DM, Green HM, et al. Beyond the Knife: the evolving nonsurgical management of oligometastatic colorectal cancer. Am Soc Clin Oncol Educ Book. 2018;38:209–219.
   PubMedGoogle Scholar
• Isoniemi H, Österlund P. Surgery combined with oncological treatments in liver metastases from colorectal cancer. Scand J Surg. 2011;100:35–41.
   PubMed Web of Science ®Google Scholar
• Tran NH, Cavalcante LL, Lubner SJ, et al. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol [Internet]. 2015;7:252–262.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Cheung WY. Integrating systemic therapies into the multimodality treatment of resectable colorectal liver metastases. Gastroenterol Res Pract. 2018;2018:1–4.
   Google Scholar
• Chen C-H, Hsieh M-C, Lao WT, et al. Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis. Am J Cancer Res [Internet]. 2018;8:1887–1898. Available from: www.ajcr.us/
   PubMed Web of Science ®Google Scholar
• Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014;25:1032–1038.
   PubMed Web of Science ®Google Scholar
• Chow FCL, Chok KSH. Colorectal liver metastases: an update on multidisciplinary approach. World J Hepatol. 2019;11:150–172.
   PubMed Web of Science ®Google Scholar
• Cieslak KP, Runge JH, Heger M, et al. New perspectives in the assessment of future remnant liver. Dig Surg. 2014;31:255–268.
   PubMed Web of Science ®Google Scholar
• Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol [Internet]. 1997;15:938–946.
   PubMed Web of Science ®Google Scholar
• Hwang M, Jayakrishnan TT, Green DE, et al. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer [Internet]. 2014;50:1747–1757.
   PubMed Web of Science ®Google Scholar
• Lim C, Doussot A, Osseis M, et al. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first. Clin Transl Oncol [Internet]. 2018;20:1274–1279.
   PubMed Web of Science ®Google Scholar
• Feng Q, Wei Y, Zhu D, et al. Timing of hepatectomy for resectable synchronous colorectal liver metastases: for whom simultaneous resection is more suitable - A meta-analysis. PLoS One. 2014;9:e104348.
   Web of Science ®Google Scholar
• Lykoudis PM, O’Reilly D, Nastos K, et al. Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg. 2014;101:605–612.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017: clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw. 2017;15:370–398.
   PubMed Web of Science ®Google Scholar
• Maher B, Ryan E, Little M, et al. The management of colorectal liver metastases. Clin Radiol [Internet]. 2017;72:617–625.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–1034.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–1075.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal. J Clin Oncol. 2014;32:2240–2247.
   PubMed Web of Science ®Google Scholar
• Brandi G, De Lorenzo S, Nannini M, et al. Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis. World J Gastroenterol. 2016;22:519–533.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist [Internet]. 2013;18:1004–1012.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422.
   PubMed Web of Science ®Google Scholar
• Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med [Internet]. 1999;341:2039–2048.
   PubMed Web of Science ®Google Scholar
• Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res [Internet]. 2011;31:4581–4587. Available from: papers2://publication/uuid/BE6AF57B-AADC-4379-9D18-E861B95E0198
   PubMed Web of Science ®Google Scholar
• Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo (Brooklyn). 2007;21:1085–1092.
   PubMed Web of Science ®Google Scholar
• Jackson WC, Tao Y, Mendiratta-Lala M, et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys [Internet]. 2018;100:950–958.
   PubMed Web of Science ®Google Scholar
• Chua TC, Saxena A, Liauw W, et al. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol. 2010;17:492–501.
   PubMed Web of Science ®Google Scholar
• Hackl C, Loss M, Klinkhammer-Schalke M, et al. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:1–10.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang ZQ, Wang FH, et al. The role of adjuvant chemotherapy for colorectal liver metastasectomy after pre-operative chemotherapy: is the treatment worthwhile? J Cancer. 2017;8:1179–1186.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–1215.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet [Internet]. 2008;371:1007–1016. Available from: papers2://publication/uuid/6F0E798C-36ED-410F-81B7-134662BF5F6B
   PubMed Web of Science ®Google Scholar
• Ciliberto D, Prati U, Roveda L, et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: A systematic review and meta-analysis of randomized controlled trials. Oncol Rep. 2012;27:1849–1856.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhou J-G, Sun Y, et al. The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis. Oncotarget [Internet]. 2016;7. Available from: http://www.oncotarget.com/fulltext/8671
   Google Scholar
• Nigri G, Petrucciani N, Ferla F, et al. Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies. Surgeon. 2015;13:83–90.
   PubMed Web of Science ®Google Scholar
• Jegatheeswaran S, Mason JM, Hancock HC, et al. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases. JAMA Surg [Internet]. 2013;148:385.
   PubMed Web of Science ®Google Scholar
• Hirokawa F, Asakuma M, Komeda K, et al. Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer? Surg Today [Internet]. 2019;49:82–89.
   PubMed Web of Science ®Google Scholar
• Khoo E, O’Neill S, Brown E, et al. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. Hpb [Internet]. 2016;18:485–493.
   PubMed Web of Science ®Google Scholar
• Sabanathan D, Eslick GD, Shannon J. Use of neoadjuvant chemotherapy plus molecular targeted therapy in colorectal liver metastases: a systematic review and meta-analysis. Clin Colorectal Cancer [Internet]. 2016;15:e141–e147.
   PubMed Web of Science ®Google Scholar
• Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601–611.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med [Internet]. 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Rong Z, Martel G, Vandenbroucke-Menu F, et al. Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey. Hpb. 2014;16:342–349.
   PubMed Web of Science ®Google Scholar
• Mitry E, Fields ALA, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol [Internet]. 2008;26:4906–4911.
   PubMed Web of Science ®Google Scholar
• Kingham TP, D’Angelica M, Kemeny NE. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol. 2010;102:988–995.
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005;352:734–735.
   PubMed Web of Science ®Google Scholar
• House MG, Kemeny NE, Gönen M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011;254:851–856.
   PubMed Web of Science ®Google Scholar
• Goéré D, Benhaim L, Bonnet S, et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg. 2013;257:114–120.
   PubMed Web of Science ®Google Scholar
• Gavriilidis P, Tobias A, Sutcliffe RP, et al. Network meta-analysis of adjuvant chemotherapy following resection of colorectal liver metastases. Gastrointest Tumors [Internet]. 2018 [cited 2019 Apr 21];5:21–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30574478
   PubMed Web of Science ®Google Scholar
• Goéré D, Pignon JP, Gelli M, et al. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973). BMC Cancer. 2018;18:1–8.
   PubMed Web of Science ®Google Scholar
• Kuhlmann K, van Hilst J, Fisher S, et al. Management of disappearing colorectal liver metastases. Eur J Surg Oncol [Internet]. 2016;42:1798–1805.
   PubMed Web of Science ®Google Scholar
• van Vledder MG, de Jong MC, Pawlik TM, et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010;14:1691–1700.
   PubMed Web of Science ®Google Scholar
• Dhir M, Sasson AR. Surgical management of liver metastases from colorectal cancer. J Oncol Pract [Internet]. 2016;12:33–39.
   PubMed Web of Science ®Google Scholar
• Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a north central cancer treatment group phase II study. J Clin Oncol. 2005;23:9243–9249.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol [Internet]. 2010 [cited 2019 Apr 22];11:38–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19942479
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, et al. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nor. J Clin Oncol [Internet]. 2007;25:1670–1676.
   PubMed Web of Science ®Google Scholar
• Shui L, Wu Y-S, Lin H, et al. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) plus bevacizumab in conversion therapy for metastatic colorectal cancer: a meta-analysis. Cell Physiol Biochem [Internet]. 2018;48:1870–1881. Available from: https://www.karger.com/Article/FullText/492508
   PubMedGoogle Scholar
• Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol [Internet]. 2015;16:1306–1315.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Masi G, et al. Initial Therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med [Internet]. 2014;371:1609–1618.
   PubMed Web of Science ®Google Scholar
• Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3:1–6.
   Web of Science ®Google Scholar
• Van Cutsem E, Köhne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med [Internet]. 2009;360:1408–1417.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Barni S. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis [Internet]. 2012;27:997–1004.
   PubMed Web of Science ®Google Scholar
• Ye L-C, Liu T-S, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol [Internet]. 2013;31:1931–1938.
   PubMed Web of Science ®Google Scholar
• Venook AP, Ou F-S, Lenz H-J, et al. Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol [Internet]. 2017 [cited 2019 Apr 26];35:3503.
   Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines version 1.2019 colon cancer. NCCN [Internet]. 2019; Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
   Google Scholar
• Mocellin S, Pilati P, Lise M, et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? [Internet]. J Clin Oncol. 2007;25:5649–5654.
   PubMed Web of Science ®Google Scholar
• Lévi FA, Boige V, Hebbar M, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27:267–274.
   PubMed Web of Science ®Google Scholar
• D’Angelica MI, Correa-Gallego C, Paty PB, et al. Phase ii trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer conversion to resection and long-term outcomes. Ann Surg [Internet]. 2015;261:353–360. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00000658-201502000-00022
   PubMed Web of Science ®Google Scholar
• Pak LM, Kemeny NE, Capanu M, et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential. J Surg Oncol [Internet]. 2018;117:634–643.
   PubMed Web of Science ®Google Scholar
• Viganò L, Capussotti L, De Rosa G, et al. Liver resection for colorectal metastases after chemotherapy. Ann Surg. 2013;258:731–742.
   PubMed Web of Science ®Google Scholar
• Hubert C, Lucidi V, Weerts J, et al. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): multicentric study of patients operated for colorectal liver metastases. Eur J Surg Oncol [Internet]. 2018 [cited 2019 Apr 24];44:1532–1538. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30093084
   PubMed Web of Science ®Google Scholar
• Zhao J, van Mierlo KMC, Gómez-Ramírez J, et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017;104:990–1002.
   PubMed Web of Science ®Google Scholar
• Massani M, Capovilla G, Ruffolo C, et al. Blood transfusions and steatohepatitis are independent risk factors for complications following liver resection for colorectal cancer liver metastases. Mol Clin Oncol [Internet]. 2017;7:529–538.
   PubMed Web of Science ®Google Scholar
• Viganò L, Rubbia-Brandt L, De Rosa G, et al. Nodular regenerative hyperplasia in patients undergoing liver resection for colorectal metastases after chemotherapy: risk factors, preoperative assessment and clinical impact. Ann Surg Oncol [Internet]. 2015;22:4149–4157.
   PubMed Web of Science ®Google Scholar
• Wicherts DA, De Haas RJ, Sebagh M, et al. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol. 2011;18:659–669.
   PubMed Web of Science ®Google Scholar
• Vigano L, De Rosa G, Toso C, et al. Reversibility of chemotherapy-related liver injury. J Hepatol [Internet]. 2017;67:84–91.
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–3116.
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Jarnagin WR, Capanu M, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol. 2011;29:884–889.
   PubMed Web of Science ®Google Scholar
• Giakoustidis A, Neofytou K, Khan A, et al. Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality. Hepatic Oncol. 2014;1:363–375.
   PubMedGoogle Scholar
• Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst [Internet]. 2005 [cited 2019 Apr 26];97:1221–1224. Available from: http://academic.oup.com/jnci/article/97/16/1221/2521344/Cetuximab-Therapy-and-Symptomatic-Hypomagnesemia
   PubMed Web of Science ®Google Scholar
• Cao Y, Liu L, Liao C, et al. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol [Internet]. 2010 [cited 2019 Apr 26];66:37–42.
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Chou JF, Boucher TM, et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol. 2016;113:477–484.
   PubMed Web of Science ®Google Scholar
• Tan HL, Lee M, Vellayappan BA, et al. The role of liver-directed therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2018;14:129–137.
   PubMed Web of Science ®Google Scholar